Okada M, Matsushima A, Katsuhata A, Aoyama T, Ando T, Inada Y
Int Arch Allergy Appl Immunol. 1985;76(1):79-81. doi: 10.1159/000233666.
Ovalbumin was modified with alpha,beta-poly[(2-hydroxyethyl)-DL-aspartamide] which had been developed as a nontoxic plasma expander. Preadministration of the modified ovalbumin suppressed both primary and secondary anti-ovalbumin IgE responses.
用已被开发作为无毒血浆扩容剂的α,β-聚[(2-羟乙基)-DL-天冬酰胺]对卵清蛋白进行修饰。预先给予修饰后的卵清蛋白可抑制初次和二次抗卵清蛋白IgE反应。